万邦德(002082.SZ)子公司药品WP107获得伦理批件

Core Viewpoint - Wanbangde (002082.SZ) has received approval from the medical ethics committee of Wenzhou Medical University for its Phase I clinical trial of the new drug WP107, aimed at treating myasthenia gravis [1] Group 1: Clinical Trial Progress - The company’s wholly-owned subsidiary, Wanbangde Pharmaceutical Group Co., Ltd., has officially commenced the Phase I clinical trial after obtaining the clinical trial approval notice from the National Medical Products Administration [1] - The trial will compare the pharmacokinetic characteristics of oral and injectable forms of Huperzine A in healthy Chinese subjects under fasting conditions [1] - The objective is to evaluate the relative bioavailability of the oral solution of Huperzine A and the safety of both formulations in a fasting state [1]